Literature DB >> 14755307

Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm.

Terrie-Anne Cock1, Sander M Houten, Johan Auwerx.   

Abstract

The nuclear receptor peroxisome proliferator-activated receptor-gamma (PPARgamma) helps to translate 'what you eat' into 'what you are' because it allows dietary fatty acids (PPARgamma ligands) to modulate gene transcription. Treatments for diabetes include PPARgamma activators, as they sensitize the body to insulin. Our understanding of PPARgamma function has recently been enhanced by a flurry of human and mouse genetic studies, and the characterization of new PPARgamma ligands. This insight has led us to propose that modulating PPARgamma activity, rather than activating it, might be the most effective strategy for treating metabolic disorders, as this will improve glucose homeostasis while preventing adipogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755307      PMCID: PMC1298993          DOI: 10.1038/sj.embor.7400082

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  63 in total

1.  Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation.

Authors:  Stephanie T de Dios; Dennis Bruemmer; Rodney J Dilley; Melanie E Ivey; Garry L R Jennings; Ronald E Law; Peter J Little
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

2.  Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity.

Authors:  Shamina M Rangwala; Ben Rhoades; Jennifer S Shapiro; A Sophie Rich; Jason K Kim; Gerald I Shulman; Klaus H Kaestner; Mitchell A Lazar
Journal:  Dev Cell       Date:  2003-10       Impact factor: 12.270

3.  Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction.

Authors:  Paul M Ridker; Nancy R Cook; Suzanne Cheng; Henry A Erlich; Klaus Lindpaintner; Jorge Plutzky; Robert Y L Zee
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-27       Impact factor: 8.311

4.  Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis.

Authors:  Evan D Rosen; Rohit N Kulkarni; Pasha Sarraf; Umut Ozcan; Terumasa Okada; Chung-Hsin Hsu; Daniel Eisenman; Mark A Magnuson; Frank J Gonzalez; C Ronald Kahn; Bruce M Spiegelman
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

Review 5.  Adipokines, inflammation, and the endothelium in diabetes.

Authors:  Waleed Aldhahi; Osama Hamdy
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

6.  Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.

Authors:  Andrew W Norris; Lihong Chen; Simon J Fisher; Ildiko Szanto; Michael Ristow; Alison C Jozsi; Michael F Hirshman; Evan D Rosen; Laurie J Goodyear; Frank J Gonzalez; Bruce M Spiegelman; C Ronald Kahn
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

7.  Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

Authors:  Oksana Gavrilova; Martin Haluzik; Kimihiko Matsusue; Jaime J Cutson; Lisa Johnson; Kelly R Dietz; Christopher J Nicol; Charles Vinson; Frank J Gonzalez; Marc L Reitman
Journal:  J Biol Chem       Date:  2003-06-11       Impact factor: 5.157

8.  Effect of meal sequence on postprandial lipid, glucose and insulin responses in young men.

Authors:  G C Burdge; A E Jones; S M Frye; L Goodson; S A Wootton
Journal:  Eur J Clin Nutr       Date:  2003-12       Impact factor: 4.016

Review 9.  Dietary fat and postprandial lipids.

Authors:  Tom A B Sanders
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

10.  Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

Authors:  David B Savage; Garry D Tan; Carlo L Acerini; Susan A Jebb; Maura Agostini; Mark Gurnell; Rachel L Williams; A Margot Umpleby; E Louise Thomas; Jimmy D Bell; Adrian K Dixon; Fidelma Dunne; Romina Boiani; Saverio Cinti; Antonio Vidal-Puig; Fredrik Karpe; V Krishna K Chatterjee; Stephen O'Rahilly
Journal:  Diabetes       Date:  2003-04       Impact factor: 9.461

View more
  47 in total

1.  Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes.

Authors:  Aimee M Powelka; Asha Seth; Joseph V Virbasius; Evangelos Kiskinis; Sarah M Nicoloro; Adilson Guilherme; Xiaoqing Tang; Juerg Straubhaar; Andrew D Cherniack; Malcolm G Parker; Michael P Czech
Journal:  J Clin Invest       Date:  2005-12-22       Impact factor: 14.808

2.  Applying gene expression, proteomics and single-nucleotide polymorphism analysis for complex trait gene identification.

Authors:  Ioannis M Stylianou; Jason P Affourtit; Keith R Shockley; Robert Y Wilpan; Fadi A Abdi; Sanjeev Bhardwaj; Jarod Rollins; Gary A Churchill; Beverly Paigen
Journal:  Genetics       Date:  2008-02-03       Impact factor: 4.562

3.  Adipose tissue expandability and the metabolic syndrome.

Authors:  Marc Slawik; Antonio J Vidal-Puig
Journal:  Genes Nutr       Date:  2007-10       Impact factor: 5.523

4.  A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice.

Authors:  Yoshihiro Shiomi; Toshimasa Yamauchi; Masato Iwabu; Miki Okada-Iwabu; Ryo Nakayama; Yuki Orikawa; Yoshichika Yoshioka; Koichiro Tanaka; Kohjiro Ueki; Takashi Kadowaki
Journal:  J Biol Chem       Date:  2015-04-23       Impact factor: 5.157

5.  Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?

Authors:  S Mittra; G Sangle; R Tandon; S Sharma; S Roy; V Khanna; A Gupta; J Sattigeri; L Sharma; P Priyadarsiny; S K Khattar; R S Bora; K S Saini; V S Bansal
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

Review 6.  Are thiazolidinediones good or bad for the heart?

Authors:  Angela M Taylor; Coleen A McNamara
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

7.  Mat1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipocyte differentiation.

Authors:  Katja Helenius; Ying Yang; Jukka Alasaari; Tomi P Mäkelä
Journal:  Mol Cell Biol       Date:  2008-11-03       Impact factor: 4.272

8.  Inverse relation between FASN expression in human adipose tissue and the insulin resistance level.

Authors:  María D Mayas; Francisco J Ortega; Manuel Macías-González; Rosa Bernal; Ricardo Gómez-Huelgas; José M Fernández-Real; Francisco J Tinahones
Journal:  Nutr Metab (Lond)       Date:  2010-01-15       Impact factor: 4.169

Review 9.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

10.  Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen.

Authors:  Terrie-Anne Cock; Jonathan Back; Florent Elefteriou; Gérard Karsenty; Philippe Kastner; Susan Chan; Johan Auwerx
Journal:  EMBO Rep       Date:  2004-09-10       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.